Pharmaceutical supply chains are no longer simply about moving products from one point to another. As medicines become more complex, markets become more interconnected, and regulatory expectations continue to rise, supply chain architecture has become a critical part of ensuring product quality, continuity and resilience.
From traceability and inventory design to cold chain engineering, digital ecosystems and AI-enabled decision-making, the challenges increasingly sit at the intersection of technology, operations, compliance and network design.
To explore these questions, we spoke with Vishal Jaiman, Senior Director – Healthcare Sector – India Subcontinent at DP World, who brings extensive experience across healthcare logistics, pharmaceutical distribution, cold chain and complex supply chain networks. In this conversation, Vishal shares his perspective on what it takes to build pharmaceutical supply chains that are not only visible and compliant, but also resilient enough to withstand real-world disruptions.
Rather than looking at technology as the answer in itself, the discussion examines the architecture behind it: how systems, processes, data, partners and physical infrastructure need to work together to create a supply chain that can perform reliably from manufacturing to the patient.
1. In pharmaceutical supply chains, batch genealogy, material traceability, serialisation, and master data are often distributed across multiple enterprise systems and external partners. From a systems architecture perspective, what principles are essential for achieving end-to-end traceability that is both audit-ready and operationally actionable? Where do such architectures most commonly fail as supply networks scale globally?
End-to-end visibility and traceability in pharmaceutical supply chains is becoming increasingly complex as the industry moves beyond conventional generics toward biologics, cell and gene therapies, and personalised medicines. These products require tighter control over material provenance, temperature-sensitive handling, batch genealogy and chain of custody across multiple systems, sites and service providers.
A common, event-based traceability architecture is essential. It should link a unique identity to each material, batch and shipment at the point of entry, eliminating ambiguity as data moves across ERP, MES, WMS, TMS, serialisation and partner platforms. Every movement, transformation and custody transfer should generate a time-stamped, auditable event, enabling both forward and backward pedigree.
Distributed ledger technologies, including blockchain where appropriate, can further strengthen trust across multiple stakeholders. This can connect raw-material provenance with manufacturing, IoT-enabled shipping conditions, storage, handling and distribution, creating a continuous digital record at the batch or unit level.
The objective is not simply visibility, but trusted, actionable traceability that supports faster recalls, stronger compliance, more effective quality investigations and greater confidence in the integrity of medicines reaching the end user.
2. Pharmaceutical inventory strategies must balance service levels, shelf life, regulatory constraints, and increasingly volatile demand. How should organizations architect inventory policies around safety stock, decoupling points, and postponement to achieve this balance? Which planning–execution disconnects most often compromise supply chain performance?
The mistake most companies make is treating inventory as one problem. It isn’t. Raw materials and finished goods behave differently, and they need separate strategies.
On the API side, start with stability. Molecules with longer stability profiles give you room to manoeuvre, and Free Trade Warehousing Zone facilities, like the capabilities offered by DP World, close to the plant let you order in bulk while still running Just-in-Time on the shop floor. You get the economics of a large order without the exposure. That single move takes a lot of the guesswork out of international transit and cargo capacity, and the cost savings show up quickly.
Finished goods are where postponement earns its keep. Hold off on secondary packaging, country-specific leaflets, and serialization for as long as the process allows, and suddenly the same stock can be pointed at whichever market is actually asking for it.
Now, where does it break? Almost always at the border, and almost always with cold chain. Planning teams build transit times that assume clean customs clearance. Reality delivers delays. If your external packaging hasn’t been validated for that extended duration, you end up re-icing in the field, which is reactive by definition. Visibility goes out the window, and buffer stock quietly inflates to cover a problem nobody planned for.
3. Excursion reporting alone does not reflect the true capability of a pharmaceutical cold chain. How should organizations engineer and measure an end-to-end thermal management system for robustness across modal transfers, customs interfaces, and regions with varying infrastructure? Which interventions have the greatest impact on improving capability rather than simply reducing deviations?
Excursion rates are a lagging indicator. They tell you what already went wrong. Real capability means asking a different question: how much stress can this system absorb before it fails?
Start with the test profiles. ISTA 7D cyclic testing up to 40°C was designed for a cooler world. Ambient temperatures are climbing, and if your packaging has only been proven to 40°C, you are validated for conditions that no longer exist on several of your lanes. Systems need to hold up past 50°C, particularly through long dwell times on tarmac and in customs yards.
Second, treat shipping qualification as a live tool rather than a checkbox you tick once a year. Dynamic lane validation looks at actual shipping volumes and seasonal swings, then sizes the thermal solution to match. That is where cost and performance stop being a trade-off.
Third, and this carries more weight than people expect, get the external packaging decision right. Active, passive, or double-stacked, the choice should follow the specific stressors of the route rather than a default that was set years ago and never revisited.
For us, as a logistics partner, the opportunity is to bring these capabilities together across the physical logistics chain, from freight forwarding and port interfaces to temperature-controlled warehousing, customs processes and inland distribution. It is about creating an end-to-end thermal management architecture where every transition is designed, every critical condition is visible, risks are predicted before they become deviations, and contingency actions can be activated quickly.
4. As pharmaceutical supply chains become increasingly dependent on interconnected platforms such as ERP, WMS, TMS, IoT, and partner systems, how should organizations approach validation of these digital ecosystems? What controls are most critical for maintaining ALCOA+ principles when data is generated and exchanged across multiple organizations?
When several partners share a supply chain, each one has to be qualified individually, including the functional touchpoints where they overlap. That overlap is what lets the next node in the chain plug in cleanly instead of becoming a translation exercise.
Governance has to be written down. Quality Technical Agreements should spell out who owns what, backed by independent audit trails on each side. On the technical side, the architecture needs to support broad API integration without modifying or reinterpreting the data in transit. The moment data gets transformed on the way through, attributability is gone.
ALCOA+ works best when it is built into the design rather than audited in afterwards. When a partner system pushes a batch update, it should do so through a uniquely attributed, secure system-to-system account, never a shared login. And edge devices matter more than they get credit for. An IoT sensor that loses connectivity should cache locally and upload securely in bulk once the network returns. Connectivity gaps are inevitable. Data gaps should not be.
5. Recent disruptions have shown that resilience must be engineered rather than assumed. How should pharmaceutical companies quantify and embed resilience into their supply chain architecture? Which network design principles or stress-testing approaches provide a more meaningful assessment than traditional KPIs such as inventory turns or on-time delivery?
Resilience comes down to two questions. How long can you keep going once something breaks, and how fast do you get back on your feet without external help?
That translates into two metrics worth building the architecture around: Time to Survive and Time to Recover. Treat them as foundational trading principles, not reporting line items.
The design rule is simple. Your TTS to TTR ratio needs to stay above 1.0. If stress testing pushes it below that line, you are looking at a structurally stressed network, and the vulnerability is real whatever your inventory turns, and on-time delivery numbers happen to say that quarter.
This means that for us, as a logistics partner, we look beyond individual logistics KPIs and assess the resilience of the entire network, from manufacturing and sourcing through ports, warehouses and transportation to the end market. Combined with scenario modelling and real-time visibility, this allows pharmaceutical companies to move from measuring resilience retrospectively to engineering it proactively and continuously testing whether the network can withstand the next disruption.
6. As pharmaceutical supply chains become more closely integrated with MES, predictive analytics, AI, digital twins, and real-time release frameworks, what architectural and governance capabilities will be essential for enabling closed-loop decision-making without compromising compliance or inspection readiness?
Classic Computer Systems Validation assumes software is validated once and then frozen. That assumption falls apart the moment you introduce a model that learns. Governance has to move toward Good Machine Learning Practice and continuous assurance.
The hard line is this: models cannot self-update in production. On-the-fly adaptation is really just unvalidated code entering a GxP environment, and no amount of performance improvement makes that acceptable.
What works instead is shadow-mode architecture. Let the retrained model run alongside the live one without touching decisions. Retrained weights go through offline validation, automated regression backtesting against historical GxP batch data, and a formal QA electronic change control before promotion. Do that, and you get the benefit of models that improve while keeping an audit trail an inspector can follow end to end.
Bringing this together at DP World means connecting port operations, freight forwarding, warehousing, cold chain, transport, trade compliance and inventory visibility through a common data architecture. The objective is not just to know where a shipment is, but to understand its condition, context and potential impact on product quality and supply continuity. This also creates an opportunity for us to position pharma logistics beyond transportation and storage: as a digitally orchestrated, quality-conscious supply-chain control layer, connecting the factory to the patient while maintaining the traceability, governance and evidence required by a highly regulated industry.
About the Guest | Vishal Jaiman
Vishal Jaiman is the Senior Director – Healthcare Sector – India Subcontinent at DP World – with extensive experience in healthcare logistics, pharmaceutical supply chains and cold chain operations across multiple geographies.
His professional journey has been shaped by a deep interest in complex markets and a focus on helping organisations navigate the operational and strategic challenges of 3PL, clinical trials, pharmaceutical distribution and temperature-controlled supply chains.
In leadership roles, Vishal has focused on building resilient teams, developing trusted relationships with key accounts and designing scalable supply chain solutions aligned with broader business objectives. His experience spans challenging geographies where operational reliability, regulatory compliance and service continuity are critical to business performance.
He is particularly engaged with the evolution of healthcare supply chains, cross-border logistics, cold chain and biopharma, and continues to contribute to industry conversations around building more resilient, technology-enabled and future-ready supply networks.
Disclaimer
The views and opinions expressed in this editorial are those of the interviewee and are based on his professional experience across pharmaceutical supply chains, networked manufacturing, regulatory strategy and technology-enabled operations. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates.
Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgement before making decisions related to manufacturing strategy, partner selection, technology transfer, or regulatory compliance.
